CIT

Across TCGA pan-cancer cohorts, CIT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CIT data layer compared with 27 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CIT mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CIT expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where CIT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	1.000	0.744	.001	32	view →
HNSC	OS	Quartile	II,III,IV	0.848	0.565	.011	16	view →
CCRCC	DFS	Median	II,III,IV	1.000	0.819	.008	8	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	3	view →
GBM	DFS	Tertile	All	0.859	0.696	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CIT–LUAD (OS)

Open the LUAD breakdown →